Redeye provides an update following SenzaGen’s Q1 report. Sales during the quarter aligned with our expectations; however, we highlight the quarterly EBITDA and argue that SenzaGen is one step closer to profitability. We only make some minor estimate changes and our fair value range remains intact.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

SenzaGen Q1 - Solid sales and EBITDA break even

© Modular Finance, source Nordic Press Releases